A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis - Rutgeerts, Paul J; Fedorak, Richard N; Hommes, Daan W; Sturm, Andreas; Baumgart, Daniel C; Bressler, Brian; Schreiber, Stefan; Mansfield, John C; Williams, Marna; Tang, Meina; Visich, Jennifer; Wei, Xiaohui; et al. (Gut, 2013)
Keywords: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - blood; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; antibody targeted therapy; Apoptosis; arthritis; autoimmune disease; Cell adhesion & migration; cell cycle; Chronic illnesses; Colitis, Ulcerative - blood; Colitis, Ulcerative - drug therapy; Crohn's disease; cytokines; Dendritic cells; Dose-Response Relationship, Drug; Double-Blind Method; drug development; Etrolizumab; Female; Gastrointestinal Agents - administration & dosage; Gastrointestinal Agents - adverse effects; Gastrointestinal Agents - blood; Gastrointestinal Agents - therapeutic use; genetics; Headache; Humans; IBD; IBD basic research; IBD clinical; IBD models; IBD–genetics; Immunoglobulins; immunology; Inflammation; Inflammatory Bowel Disease; inflammatory bowel disorders; Infusions, Intravenous; Injection; Injections, Subcutaneous; Integrins; Intravenous administration; Lymphocytes; Male; Middle Aged; Migration; Monoclonal antibodies; Pharmacokinetics; Remission; Retention; rhuMAb β7; safety; Severity of Illness Index; signal transduction; Studies; Treatment Outcome; Ulcerative colitis; Wound healing; Young Adult; United States--US; IBD basic research; cell cycle; rhuMAb β7; signal transduction; IBD clinical; IBD models; drug development; Etrolizumab; apoptosis; Crohn's disease; IBD; autoimmune disease; antibody targeted therapy; integrins; dendritic cells; genetics; arthritis; safety; inflammatory bowel disorders; pharmacokinetics; cytokines; ulcerative colitis; immunology; IBD–genetics